# Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

> **NCT04143282** · PHASE2 · COMPLETED · sponsor: **Hager salah el din** · enrollment: 250 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Metformin plus chemotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04143282
- **Lead sponsor:** Hager salah el din
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-20
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-06-30
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143282, "Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04143282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*